Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
The high mortality rate in COVID-19 patients has been linked to cytokine release syndrome, commonly referred to as cytokine storm, which is an excessive and dysregulated production of proinflammatory cytokines by the body’s immune system.
In this webinar, we will highlight how Eurofins DiscoverX functional cell-based assays are supporting active clinical programs focused on developing and repurposing therapeutic drugs for treatment of COVID-19, particularly in managing proinflammatory cytokines associated with high mortality rate in COVID-19 patients. We will present case studies for target-specific, ready-to-plate qualified bioassays, and discuss how they accelerate drug development and QC Lot Release programs for biologic drugs for COVID-19.
- Functional, MOA-reflective cell-based assays for screening through QC lot release
- How qualified bioassays can accelerate drug release programs
- Assays that support both small molecules and biologics for COVID-19 drug development
Date: Wednesday, Oct. 28, 2020
Time: 8:00am PDT / 11:00am EDT
Duration: 45 min
Gaurav Agrawal, Ph.D.
Scientific Development Manager, Marketing Department